GlycoMimetics (NASDAQ:GLYC – Get Free Report) and Orgenesis (NASDAQ:ORGS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Analyst Ratings This is a summary of recent recommendations […]
Research analysts at StockNews.com initiated coverage on shares of GlycoMimetics (NASDAQ:GLYC – Get Free Report) in a report released on Thursday. The firm set a “hold” rating on the biotechnology company’s stock. Separately, HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of GlycoMimetics in a report on Thursday, August […]
Beirne Wealth Consulting Services LLC raised its holdings in shares of GlycoMimetics, Inc. (NASDAQ:GLYC – Free Report) by 25.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,000 shares of the biotechnology company’s stock after acquiring an additional 10,000 shares during the […]
GlycoMimetics, Inc. (NASDAQ:GLYC – Get Rating) crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.05 and traded as low as $1.77. GlycoMimetics shares last traded at $1.80, with a volume of 226,481 shares changing hands. Analyst Ratings Changes GLYC has […]
NEA Management Company LLC lessened its holdings in shares of GlycoMimetics, Inc. (NASDAQ:GLYC – Get Rating) by 1.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 8,967,706 shares of the biotechnology company’s stock after selling 121,335 shares during the period. GlycoMimetics makes up approximately 1.5% of NEA […]